25 May 2013
Keywords: MAP Thera, Levadex, Migraine, USA, FDA, Market forecast, Allergan
Article | 28 March 2012
Shares of USA-based MAP Pharmaceuticals (Nasdaq: MAPP) plunged 24% to $13.01 in early trading yesterday, after the firm said it has received ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 March 2012
24 May 2013
© 2013 thepharmaletter.com